Workflow
AZEK Company Inc. (AZEK.US)Notes from the Road
Goldman Sachs· 2024-08-14 02:50
13 August 2024 | 8:51PM EDT AZEK Company Inc. (AZEK): Notes from the Road Earlier today, we hosted investor meetings in Boston with Azek's CEO Jesse Singh, Residential Segment CFO Ryan Lada, and Head of IR Eric Robinson. Discussions focused on company-specific efforts to drive above-market growth along with the path for margins as it realizes operating leverage and a more favorable cost structure. Overall, we come away with greater confidence in the ability to continue to outperform, even as broader R&R rem ...
Atara Biotherapeutics Inc. (ATRA.US) 2Q EPS: CEO transition; First CD19 oncology data now in 1Q25, with autoimmune to follow
Goldman Sachs· 2024-08-14 02:49
13 August 2024 | 9:20AM EDT Atara Biotherapeutics Inc. (ATRA): 20 EPS: CEO transition; First CD19 oncology data now in 1025, with autoimmune to follow In tandem with 2Q EPS, ATRA announced a CEO transition in which Cokey Nguyen (ATRA's Chief Scientific and Technical Officer) will succeed Pascal Touchon effective September 9. Further updates included delaying the timing for first Ph1 ATA3219 (allogeneic CD19 CAR T) data in relapsed/refractory B-cell non-Hodgkin's lymphoma to 1Q25 vs. 4Q24 prior on slower pat ...
Americas Advisors: Weekly M&A activity as of 08.13.2024
Goldman Sachs· 2024-08-14 02:49
13 August 2024 | 9:10AM EDT Americas Advisors: Weekly M&A activity as of 08.13.2024. Please find below summary tables to highlight weekly M&A trends for the independent advisors, bulge bracket firms, independent investment banks and mid-cap brokers. James Yaro +1(212)902-1913 | iames.e.varo@gs.com Goldman Sachs & Co. LLC Richard Ramsden +1(212)357-9981 richard.ramsden@gs.com Goldman Sachs & Co. LLC Songqing Jiang +1(212)934-0308 songqing.jang@gs.com Goldman Sachs & Co. LLC Ishan Rai, CFA +1(332)245-7603 / i ...
Amotiv Ltd. (AOV.US): FY24 First Take: Result in~line with May guidance; Buy
Goldman Sachs· 2024-08-14 02:49
14 August 2024 | 8:53AM AEST Amotiv Ltd. (AOV.AX): FY24 First Take: Result in-line with May guidance; Buy Amotiv (AOV) have reported their FY24 results, the first under their new name and new segmentation. GS take: Result largely in-line with expectations with minimal specific guidance provided. Buy. Key takeaways: ■ Group Ebita of A$194.6m marginally above May guidance of 'at least A$193.5m'. APG achieved Ebita of A$63.1m (May guidance of A$63m). Performance in Lighting (+7.3% organic; +13.3% with acquisit ...
Asia~Pacific Portfolio Strategy: Asian equity market daily update
Goldman Sachs· 2024-08-14 02:49
13 August 2024 | 8:31 PM SGT Asia-Pacific Portfolio Strategy: Asian equity market daily update: The MXAPJ Index was flat today. Indonesia and Philippines markets outperformed, while India and Australia markets underperformed. Within MXAPJ sectors, Info Tech and Comm Serv led while Health Care and Materials lagged. MSCI Japan rose 3.1% today. For a detailed analysis, please see Weathering summer storms, August 7, 2024. Exhibit 1: The MXAPJ index has gained 5.2% YTD after gaining 5% in 2023, particularly led ...
Allos SA (ALOS3.SA)2Q24 First Take:Improving Fundamentals; Income Statement Within Expectations
Goldman Sachs· 2024-08-14 02:49
13 August 2024 | 10:10PM BRT Allos SA (ALOS3.SA): 2024 First Take:Improving Fundamentals; Income Statement Within Expectations Jorel Guilloty +55(11)3372-3522 jorel.quilloty@as.com Goldman Sachs do Brasil CTVM S.A. Our take: We expect Allos 2024 results to have a muted impact on shares. Net revenue and NOI came within expectations, while property EBITDA and FFO came slightly ahead driven by better SG&A. Fundamentals generally saw an improvement with occupancy rising 60 bps y/y to 96.3%. Occupancy cost saw a ...
Americas Healthcare:Biotechnology,Boston Biotech Bus Tour~Day 1 takeaways
Goldman Sachs· 2024-08-14 02:49
13 August 2024 | 5:49AM EDT Americas Healthcare: Biotechnology: Boston Biotech Bus Tour - Day 1 takeaways We met with the management teams from LNTH, BPMC, KYMR, and RYTM during Day 1 of our Boston biotechnology bus tour. We offer our detailed takeaways below. Takeaways Lantheus Holdings (LNTH, Not Covered) We hosted Brian Markison (CEO), Paul Blanchfield (President), and Robert Marshall (CFO), as well as representatives of the company's investor relations team during our 2024 Boston Biotech Bus Tour. The c ...
Americas Restaurants: SBUX appoints current CEO of CMG as new Chairman/CEO
Goldman Sachs· 2024-08-14 02:49
13 August 2024 | 9:27AM EDT Americas Restaurants: SBUX appoints current CEO of CMG as new Chairman/CEO This morning, SBUX announced that Brian Niccol has been appointed chairman and chief executive officer, with the current CEO/chairman Laxman Narasimhan stepping down effective immediately. Mr. Niccol will join the company on September 9, with current CFO Rachel Ruggeri serving as interim CEO until then. CMG's Board of Directors has appointed Scott Boatwright, Chief Operating Officer, as Interim CEO. SBUX: ...
Americas Energy Key learnings from earnings season that support The Future of Utilities Capex; Buy SRE, PWR
Goldman Sachs· 2024-08-14 02:48
13 August 2024 | 7:45PM EDT Americas Energy Key learnings from earnings season that support The Future of Utilities Capex; Buy SRE, PWR The Future of Utilities Capex Explore > With second quarter earnings season now behind us, we reflect on key learnings that support The Future of Utilities Capex, our constructive view on Utilities, and our Buy rating on Quanta Services (PWR). We believe commentary from utilities continues to point to positive capital spending revisions as we look to the Fall and early 2025 ...
Americas Agriculture: Proposed changes in LCFS
Goldman Sachs· 2024-08-14 02:48
13 August 2024 | 11:07AM EDT Americas Agriculture: Proposed changes in LCFS Late Monday (8/12), the California Air Resources Board (CARB) proposed amendments to the Low Carbon Fuel Standard (LCFS), subject to a public hearing & vote on November 8th. This follows prior proposal amendments issued in December 2023 that had been scheduled for hearing & vote in February 2024 that was ultimately postponed. Key highlights of proposed changes 1) 9% step-down in 2025 CI reduction. CARB is proposing to modify the nea ...